Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Impressive Third Quarter Earnings
On October 24, T. Rowe Price reported third quarter earnings per share of 87 cents, topping the Zacks Consensus Estimate of 84 cents by 3.6% and the year-ago earnings of 71 cents by 22.5%. The improvement was primarily due to impressive top-line growth and increased assets under management, partly offset by elevated operating expenses.
Net revenue climbed 13.3% year over year to $769.7 million, primarily due to an increase in investment advisory fees. However, total operating expenses rose 6.9% year over year to $410.8 million as a result of high distribution and servicing costs, depreciation and amortization expense, as well as compensation and related costs.
Total assets under management increased to $574.4 billion as of September 30, 2012, up 6% from $541.7 billion as of June 30, 2012. Income of $28.4 billion and net cash inflows of $4.3 billion positively impacted assets under management in the reported quarter.
Earnings Momentum Pushes Higher
The Zacks Consensus Estimate for 2012 is up 3.7% to $3.36 in the past 30 days as 16 of 19 total estimates moved higher. The Zacks Consensus Estimate for 2013 advanced 1.6% to $3.80, based on upward revisions from 14 of 21 estimates.
The Zacks Consensus Estimate for 2012 reflects year-over-year growth of about 14.9%, while the expected growth rate for 2013 is 13.3%.
Dividend Payment
T. Rowe Price hiked its dividend by 10% to 34 cents per share early this year. The current dividend rate affirms an annual yield of 2.2%. This marked T. Rowe Prices 26th consecutive annual dividend increase, reflecting the companys ability to return value to shareholders.
Premium Valuation
Shares of T. Rowe Price currently trade at 18.9x 12-month forward earnings, a 41.0% premium to the peer group average of 13.4x. Its price to book ratio of 4.2 is at a significant premium to the peer group median of 0.9. Given its strong fundamentals, the premium valuation is justified.
Moreover, the company has a trailing 12-month ROE of 22.5% compared with the peer group average of 12.2%. This implies that the company reinvests its earnings more efficiently than its peer group.
Chart Shows Strength
T. Rowe Price has been continuously outperforming the S&P 500 and its 200 days moving average over the last three months, exhibiting a steady growth trend. The year-to-date return for the stock came in at 11.9% compared with the S&P 500s return of 8.0%.
With rising estimates, a strong earnings growth expectation and a decent dividend yield, T. Rowe Price looks like a promising growth and income driver.
Headquartered in Baltimore, Maryland, T. Rowe Price is an asset management company that was founded in 1937. It provides a host of mutual funds, sub-advisory services and separate account management for individual and institutional investors, retirement plans as well as financial intermediaries. The company operates worldwide from the U.S., the U.K., Hong Kong, Japan and Singapore. The company has a market cap of about $16.1 billion. GAMCO Investors, Inc. (GBL) is a Zacks #1 Rank (Strong Buy) stock in the same industry.
Want More of Our Best Recommendations?
Zacks' Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Then each week he hand-selects the most compelling trades and serves them up to you in a new program called Zacks Confidential.
Learn More>>
Get the full Analyst Report on TROW - FREE